MRC Strategic Review of Neurodegeneration - Report of the Strategic Review Group
The review was undertaken to advise MRC on how best to manage it’s funding for research and training relevant to neurodegeneration, taking into account: • MRC’s interests in Alzheimer’s disease and other dementias, Parkinson’s disease, Huntington’s disease, multiple sclerosis, motor neurone disease and prion disease. • MRC’s funding for dedicated centres of excellence in the area – the MRC Prion Unit and the MRC Centre for Neurodegeneration Research. • The worldwide development of the field, in particular in the USA. • The current and future opportunities in basic and translational research. The review group was chaired by Professor Christopher Kennard, Chair of the MRC Neuroscience and Mental Health Board, and included scientists with broad expertise in neurodegeneration and related neurosciences from both academia and industry.
Similar entries
- Policy Advocacy in Northern Ireland
- The Legal and Policy Challenges of Financial Elder Abuse
- China's octogenarian population to grow by 1 million annually
- Healthy Ageing: The Role of Nutrition & Lifestyle
- National framework for palliative care in dementia pilot
- ROI National framework for palliative care in dementia pilot
- Pensioner's death must act as a wake up call for communities
- All Roads lead to Paris
- Systems Biology Approches to Parkinson's disease
- Report of the Interdepartmental Working Group on Long Term Care, 2006
